MacroGenics, Inc. (MGNX) Balance Sheet

The equity base has contracted from $120.1M in 2024Q3 to $21.2M in 2026Q1 before rebounding to $42.9M, a pattern that points to losses and capital events consuming book value. Investors should monitor whether the latest rebound reflects durable capital formation or a temporary inflow that reverses in subsequent quarters.

The recurring step-ups and reversals in total debt suggest short-dated or event-linked facilities rather than a long-term capital structure. The volatility in D/E makes leverage highly sensitive to the equity denominator, so the ratio alone may overstate or understate underlying obligations. Refinancing timing and maturity profile warrant further investigation given the amplitude of these swings.

A high current ratio here is partly a function of a shrinking non-cash liabilities base relative to current assets, so it does not necessarily indicate durable buffer strength. The decline in cash across the period, combined with persistent operating cash burn noted in prior cash flow findings, suggests the runway depends on continued access to capital. This implies liquidity may be more fragile than the headline ratio suggests.

The consistent PP&E decline is consistent with low capital intensity noted in the cash flow analysis, implying the business model is asset-light and not dependent on physical infrastructure. The absence of goodwill removes impairment risk but also means no acquired intangible base is carried forward. Asset quality therefore rests largely on cash and receivables rather than operating infrastructure.

The deficit magnitude means each equity raise is largely absorbed by ongoing losses, leaving little cushion against further operating shortfalls. Equity quality is therefore low in the sense that book value depends on continued external funding rather than retained profitability. Dilution and stock-based compensation are not separately disclosed in the provided data, so their contribution cannot be assessed here.

Declining deferred revenue alongside lumpy reported revenue points to milestone recognition consuming prior advances without equivalent replenishment. Remaining performance obligations are not provided in the supplied data, so the forward contracted base cannot be fully sized. Investors should monitor whether new collaboration or licensing agreements rebuild this balance.